Genetic mutations in the tumours of kidney cancer patients can predict their risk of relapse, according to a new study published this week in the Journal of the American Association for Cancer Research. An international consortium led by a team from McGill University, in collaboration with the University of Leeds in the UK, has reportedly achieved a major breakthrough in kidney cancer treatment research